Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $575.00

Intuitive Surgical (NASDAQ:ISRG) had its target price lifted by Jefferies Financial Group from $475.00 to $575.00 in a research note released on Monday morning.

ISRG has been the topic of a number of other research reports. Wells Fargo & Company upped their price target on shares of Intuitive Surgical from $630.00 to $687.00 and gave the stock an “overweight” rating in a research note on Friday, January 24th. Leerink Partners upped their target price on shares of Intuitive Surgical from $489.00 to $502.00 in a research note on Thursday, October 17th. Truist Financial raised their price target on shares of Intuitive Surgical from $640.00 to $666.00 and gave the company a “buy” rating in a research report on Friday, January 24th. Oppenheimer reaffirmed a “market perform” rating on shares of Intuitive Surgical in a research report on Friday, October 18th. Finally, Bernstein Bank lifted their target price on Intuitive Surgical from $655.00 to $700.00 and gave the stock an “overweight” rating in a report on Monday. One analyst has rated the stock with a sell rating, five have assigned a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $613.10.

Intuitive Surgical Trading Down 0.2 %

Shares of NASDAQ:ISRG opened at $572.71 on Monday. The stock has a fifty day simple moving average of $548.70 and a two-hundred day simple moving average of $507.04. Intuitive Surgical has a 12-month low of $364.17 and a 12-month high of $616.00. The stock has a market capitalization of $203.99 billion, a price-to-earnings ratio of 92.08, a PEG ratio of 5.19 and a beta of 1.39.

Insider Transactions at Intuitive Surgical

In related news, insider Jamie Samath sold 22,903 shares of Intuitive Surgical stock in a transaction on Friday, November 8th. The shares were sold at an average price of $525.00, for a total transaction of $12,024,075.00. Following the transaction, the insider now owns 8,757 shares in the company, valued at approximately $4,597,425. The trade was a 72.34 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Robert Desantis sold 376 shares of the company’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $539.00, for a total value of $202,664.00. Following the completion of the transaction, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at approximately $2,967,734. This trade represents a 6.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,843 shares of company stock worth $15,357,560 in the last three months. Corporate insiders own 0.90% of the company’s stock.

Hedge Funds Weigh In On Intuitive Surgical

Institutional investors have recently added to or reduced their stakes in the company. Berbice Capital Management LLC bought a new stake in shares of Intuitive Surgical in the 4th quarter worth about $26,000. Godsey & Gibb Inc. raised its holdings in shares of Intuitive Surgical by 140.0% in the third quarter. Godsey & Gibb Inc. now owns 60 shares of the medical equipment provider’s stock worth $29,000 after buying an additional 35 shares during the period. MidAtlantic Capital Management Inc. purchased a new stake in Intuitive Surgical in the third quarter worth $33,000. Decker Retirement Planning Inc. bought a new stake in Intuitive Surgical during the 4th quarter valued at about $36,000. Finally, Capital Performance Advisors LLP bought a new stake in shares of Intuitive Surgical during the third quarter valued at approximately $38,000. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.